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Abstract
BACKGROUND: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous 
adverse drug reactions. Human leukocyte antigens (HLA) may play an important role in the pathogenesis of 
SJS/TEN.
AIMS: This study aims to identify HLA-B alleles in Vietnamese patients with SJS/TEN and to investigate the possible 
link between HLA-B alleles and causative drugs. 
MATERIALS AND METHODS: Sixty patients including SJS (30 patients) and TEN (30 patients) were enrolled in a 
cross-sectional descriptive study at two hospitals in Hanoi, Vietnam, from July 2018 to July 2019. Clinical features 
and laboratory findings were noted, HLA-B alleles were analyzed by the polymerase chain reaction (PCR)-sequence-
specific oligonucleotide assay and LuminexTM Multiplex Technology.
RESULTS: The most common HLA-B allele was HLA-B*15:02 (41.7%) followed by HLA-B*58:01 (25%) and 
HLA-B*46:01 (15%). Of the 25 patients possessing HLA-B*15:02 allele, culprit medicines were carbamazepine 
(13 patients; 52%), traditional medicine (two patients; 8%), and unknown drugs (seven patients; 28%). Of the 15 
patients carrying HLA-B*58:01 allele, there were 13 patients whose offending medicine was allopurinol. Of the eight 
patients whose culprit drug was traditional medicine, there were 6 patients (75%) carrying HLA-B*51:02. Patients 
who carry HLA-B*15:02 were found to have 4 times higher risk of developing carbamazepine-induced SJS/TEN as 
compared with the tolerant control group (OR=4.17; 95% CI=2.07–8.37; p < 0.001).
CONCLUSION: HLA-B*15:02 was the most common HLA-B allele in Vietnamese patients with SJS/TEN. In 
traditional medicine-induced SJS/TEN patients, HLA-B*51:02 allele might play an important role. The link between 
the HLA-B genotypes and causative drugs may suggest physicians to avoid risk medications for certain patients.
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Introduction
Stevens-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TEN) are severe cutaneous 
adverse drug reactions (SCARs) [1]. Although their 
incidence is of 2 per million per year, they are life 
threatening with a mortality rate of 5–30% [2], [3]. The 
common culprit drugs are allopurinol, carbamazepine, 
phenytoin, phenobarbital, lamotrigine, abacavir, and 
others [2], [3], [4], [5]. The time between the date of 
taking medicine and the onset of symptoms ranges 
from some days to 2 months [2], [4].
The main manifestations of SJS/TEN are 
apoptosis [6] and/or necroptosis [7] of epidermal 
keratinocytes that are initiated by cytotoxic T lymphocytes 
with the presence of culprit drugs [1], [6], [8]. Based on 
the percentage of necrotic skin area, SJS and TEN are 
classified by Bastuji-Garin as follows: (1) SJS is defined 
as epidermal detachment <10% body surface area 
(BSA) plus widespread purpuric macules or flat atypical 
targets; (2) overlap SJS/TEN is defined as detachment 
of 10–30% BSA plus widespread purpuric macules or 
flat atypical targets; (3) TEN with spots (detachment 
>30% BSA plus widespread purpuric macules or flat 
atypical targets); and (4) TEN without spots (detachment 
>30% BSA with loss of large epidermal sheets without 
purpuric macules or target lesions) [9].
Many studies have indicated associations 
between the human leukocyte antigens (HLA) and 
SCARs [1], [10], [11], [12], [13]. In Han Chinese 
population, there is a strong association between 
HLA-B*15:02 allele with SJS/TEN due to some 
aromatic antiepileptic drugs such as carbamazepine, 
phenytoin, phenobarbital, and lamotrigine [14], and 
between HLA-B*58:01 allele and allopurinol-induced 
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SJS/TEN [10], [15]. Some SJS/TEN drug associations 
have been also added, for example, HLA-B*57:01 
with abacavir in Caucasians [13], [15], [16] and HLA-
A*31:01 with carbamazepine in Japanese [17]. Studies 
in Vietnam have shown the association between HLA-B 
alleles and specific drug-induced SJS/TEN such as 
carbamazepine [18] and allopurinol [19]. In addition, 
common HLA-B alleles among general Kinh population 
(the major ethnicity in Vietnam) have been studied [20].
There has been no study with regard to HLA-B 
genotypes of SJS/TEN generally. The aim of this study 
was to identify HLA-B alleles among Vietnamese 
patients with SJS/TEN and the possible link between 
HLA-B alleles and causative drugs.
Materials and Methods
Subjects
The study was conducted at National Hospital 
of Dermato-venereology and Bach Mai Hospital in 
Hanoi, Vietnam, from July 2018 to July 2019. In total, 
60 patients including 30 SJS and 30 TEN were enrolled 
in our study. Clinical features and laboratory findings 
were recorded for each patient. We investigated all 
medicines, including the over the counter, that the 
patients took over a period of 2 months before the onset 
of the conditions. Other pieces of information were also 
obtained (reasons for using drugs, ethnicity, and allergy 
history). The patients were examined as regards their 
general condition, cutaneous, and mucous membrane 
lesions.
SJS and TEN were diagnosed and classified 
based on Bastuji-Garin criteria [9]. Calculation of 
necrotic skin and epithelial sloughing areas was based 
on burn area estimation (Lund-Browder formula) [21]. 
We determined the most culprit drugs using ALDEN 
algorithm [5].
DNA isolation and HLA-B typing
DNA extraction (MagNA Pure Compact nucleic 
acid purification kit, Roche Diagnostics Ltd., USA) 
was performed based on magnetic bead technology. 
DNA was aliquoted and stored at −20°C before HLA 
typing. Polymerase chain reaction (PCR)-sequence-
specific oligonucleotide assay and LuminexTM 
Multiplex Technology were used to analyze HLA-B 
alleles. To summarize, PCR products were hybridized 
against a panel of oligonucleotide probes coated on 
polystyrene microspheres that have sequences which 
complement stretches of polymorphic sequence within 
the target HLA-B alleles. Using a colorimetric reaction 
and fluorescence detection technology, we were able 
to see the amplicon probe complex. Data analysis for 
the HLA-B assays was performed with HLA fusion 
TM2.0 software. This typing was conducted at National 
Institute of Hematology and Blood Transfusion in Hanoi, 
Vietnam.
Ethical clearance
The study was approved by the Ethical Review 
Committee on Research Involving Human Subjects, 
Hanoi Medical University, Hanoi, Vietnam (Number 
04NCS17, dated February 8, 2018). Written consent 
was obtained from all participants.
Results
There were 30 patients with SJS and 30 
patients with TEN, no patients with overlapping 
SJS/TEN. All patients were Kinh ethnicity. The patient’s 
characteristics are shown in Table 1. The mean age 
was 52 years (range 19–77). The most common age 
group was over 50 years old (65%). The sex distribution 
was equal (male: 53.3%; female: 46.7%). Reasons 
for using causative drugs were gout disease (21.7%), 
arthralgia (18.3%), epilepsy (15%), headache (5%), 
other reasons (20%), and unknown (20%). The most 
frequent causative drugs used were allopurinol (13 
patients; 21.7%), carbamazepine (13 patients; 21.7%), 
and traditional medicine (eight patients; 13.2%). Other 
medications were less common, such as nonsteroidal 
anti-inflammatory drugs (diclofenac, phenylbutazone, 
and piroxicam), lamotrigine, thalidomide, and antibiotics 
(zidocin). There were 33.2% of patients with unknown 
culprit drugs.
Table 1: Characteristics of patients with SJS/TEN (n=60)
Characteristics SJS (n=30) TEN (n=30) SJS/TEN (n=60)
Age, year 51.2 ± 16.7 52.8 ± 15.5 52 ± 16
Range 19–77 19–77 19–77
Group of age, n (%)
<30 3 (10) 3 (10) 6 (10)
30–39 5 (16.7) 3 (10) 8 (13.3)
40–50 4 (13.3) 3 (10) 7 (11.7)
>50 18 (60) 21 (70) 39 (65)
Sex, n (%)
Male 16 (53.3) 16 (53.3) 32 (53.3)
Female 14 (46.7) 14 (46.7) 28 (46.7)
Indications of culprit drugs, n (%)
Gout disease 9 (30) 4 (13.3) 13 (21.7)
Arthralgia 5 (16.7) 6 (20) 11 (18.3)
Epilepsy 4 (13.3) 5 (16.7) 9 (15)
Headache 2 (6.7) 1 (3.3) 3 (5)
Other reasons 4 (13.3) 8 (26.7) 12 (20)
Unknown cause 6 (20) 6 (20) 12 (20)
Causative drugs, n (%)
Allopurinol 9 (30) 4 (13.3) 13 (21.7)
Carbamazepine 7 (23.4) 6 (20) 13 (21.7)
Traditional medicine 0 (0) 8 (26.7) 8 (13.2)
NSAIDs (diclofenac, phenylbutazone, 
and piroxicam)
1* (3.3) 2 (6.7) 3 (5.1)
Others (lamotrigine, thalidomide, and 
zidocin)
1** (3.3) 2 (6.7) 3 (5.1)
Unknown drugs 12 (40) 8 (26.6) 20 (33.2)
SJS: Stevens-Johnson syndrome, TEN: Toxic epidermal necrolysis, NSAIDs: Nonsteroidal anti-
inflammatory drugs, *phenylbutazone; **zidocin.
A total of 60 patients were underwent HLA-B 
typing. The results (as shown in Table 2) demonstrated 
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that the most common HLA-B allele was HLA-B*15:02 
(25/60 patients; 41.7%) followed by HLA-B*58:01 
(15/60 patients; 25%) and HLA-B*46:01 (9/60 patients; 
15%). Other less common alleles were HLA-B*51:01 
(eight patients; 13.2%); HLA-B*13:01 (eight patients; 
13.2%); and HLA-B*07:05 (four patients; 6.6%).
Table 2: HLA-B genotypes in Vietnamese patients with SJS/
TEN (n=60)
Patient No. Diagnosis Causative medicine Allele 1 Allele 2
1 SJS Carbamazepine 15:02 15:25
2 SJS Carbamazepine 15:02 40:01
3 SJS Carbamazepine 15:02 51:01
4 SJS Carbamazepine 15:02 56:04
5 SJS Carbamazepine 15:02 15:02
6 SJS Carbamazepine 15:02 46:01
7 SJS Carbamazepine 15:02 46:01
8 TEN Carbamazepine 15:02 44:03
9 TEN Carbamazepine 15:02 40:01
10 TEN Carbamazepine 15:02 55:02
11 TEN Carbamazepine 15:02 54:01
12 TEN Carbamazepine 15:02 13:01
13 TEN Carbamazepine 15:02 13:01
14 SJS Unknown 15:02 51:02
15 SJS Unknown 15:02 13:01
16 SJS Unknown 15:02 73:01
17 SJS Unknown 15:02 57:01
18 SJS Unknown 15:02 40:01
19 TEN Unknown 15:02 35:05
20 TEN Unknown 15:02 15:02
21 TEN Traditional medicine 15:02 51:02
22 TEN Traditional medicine 15:02 54:01
23 SJS Allopurinol 15:02 58:01
24 SJS Zidocin 15:02 15:02
25 TEN Piroxicam 15:02 15:02
26 SJS Allopurinol 58:01 13:02
27 SJS Allopurinol 58:01 57:01
28 SJS Allopurinol 58:01 40:06
29 SJS Allopurinol 58:01 13:01
30 SJS Allopurinol 58:01 46:01
31 SJS Allopurinol 58:01 51:01
32 SJS Allopurinol 58:01 38:02
33 SJS Allopurinol 58:01 40:01
34 TEN Allopurinol 58:01 40:01
35 TEN Allopurinol 58:01 46:01
36 TEN Allopurinol 58:01 56:04
37 TEN Allopurinol 58:01 40:01
38 TEN Unknown 58:01 07:02
39 SJS Unknown 58:01 35:05
40 SJS Unknown 07:05 46:01
41 SJS Unknown 38:02 46:01
42 TEN Unknown 15:25 46:01
43 TEN Unknown 13:01 51:02
44 TEN Unknown 56:04 51:02
45 SJS Unknown 13:01 38:02
46 SJS Unknown 13:01 07:02
47 SJS Unknown 07:05 51:01
48 TEN Unknown 07:05 51:01
49 SJS Unknown 56:02 38:02
50 TEN Unknown 07:05 73:01
51 TEN Traditional medicine 51:02 46:01
52 TEN Traditional medicine 15:01 51:02
53 TEN Traditional medicine 15:21 51:02
54 TEN Traditional medicine 37:01 51:02
55 TEN Traditional medicine 15:25 51:02
56 TEN Traditional medicine 54:01 54:01
57 TEN Diclofenac 13:01 51:01
58 SJS Phenylbutazone 35:05 38:02
59 TEN Thalidomide 15:21 57:01
60 TEN Lamotrigine 15:21 46:01
SJS: Stevens-Johnson syndrome, TEN: Toxic epidermal necrolysis, HLA-B: Human leukocyte antigen-B.
Of the 25 patients possessing HLA-B*15:02 
allele, the culprit drugs were carbamazepine among 
13 patients (52%), traditional medicine 2 patients (8%), 
allopurinol 1 patient (4%) (who had HLA-B phenotype 
that was 15:02 and 58:01), piroxicam 1 patient (4%), 
zidocin (metronidazole and spiramycin) 1 patient 
(4%), and unknown drugs 7 patients (28%). Of the 15 
patients with HLA-B*58:01, there were 13 patients with 
allopurinol-induced SJS/TEN and two patients with 
unknown causative drugs. Among eight patients with 
traditional medicine-induced SJS/TEN, there were six 
HLA-B*51:02 allele carriers (75%).
We compared the risk of carbamazepine-
induced SJS/TEN between the 13 carbamazepine-
induced SJS/TEN patients carrying HLA-B*15:02 with 
the control group (epilepsy tolerating carbamazepine) 
from a previous study in Vietnam [18]. A significant 
association between carbamazepine-induced SJS/TEN 
and HLA-B*15:02 was found when compared with the 
tolerant control group (OR=4.17; 95% CI=2.07–8.37; 
p < 0.001). However, there was no significant association 
between carbamazepine-induced SJS/TEN and 
HLA-B*46:01 (OR=0.32; 95% CI=0.06–1.8; p = 0.184), 
as shown in Table 3.
Table 3: Correlation between HLA-B*15:02, HLA-B*46:01, and 
phenotypes (carbamazepine-induced SJS/TEN)
Allele positive SJS/TEN (n=13) Control** (n=25) OR (95% CI) p-value
HLA-B*15:02 13 6 4.17 (2.07–8.37) <0.001
HLA-B*46:01 2 9 0.32 (0.06–1.8) 0.184
SJS: Stevens-Johnson syndrome, TEN: Toxic epidermal necrolysis, HLA-B: Human leukocyte antigen-B; 
OR: Odds ratio, CI: Confidence interval, **following the study of Nguyen et al. [18].
Discussion
Among 60 SJS/TEN patients, HLA-B*15:02 
was the most common allele which is higher than that 
in general Kinh population [20]. This finding might be 
due to the fact that all participants in our study were 
SJS/TEN patients, whose the most frequent culprit 
drug was carbamazepine. Of the 25 HLA-B*15:02 
carriers in this study, there were 13 carbamazepine-
induced SJS/TEN patients (52%). Studies in Asian 
countries have demonstrated the strong association 
between carbamazepine-induced SJS/TEN and 
HLA-B*15:02 [14], [15], [22]. A previous study in Vietnam 
shows the most common HLA-B allele among general 
population is HLA-B*15:02 [20]. While, a study in Korean 
population shows that HLA-B*44:03 is the most frequent 
type in HLA-B genes; allele frequency of HLA-B*15:02 
is 0.3% [23]. Among Thai population, the most common 
HLA-B alleles observed is HLA-B*46:01 (11.5%), while 
the HLA-B*15:02 allele frequency is 8.2% [24]. These 
results show the diversity of HLA-B polymorphisms 
in different ethnicities. The high frequency of HLA-B 
pharmacogenomic markers in population emphasizes 
the importance of such screening to predict and avoid 
SCARs [13], [24], [25].
In the present study, there were 15 out of 
60 patients carry HLA-B*58:01 allele (25%). Among 
them, there were 13 patients with allopurinol-induced 
SJS/TEN and two patients with unknown drug-induced 
SJS/TEN. The strong association between HLA-
B*58:01 and allopurinol-induced SJS/TEN has been 
shown in Asian [10] as well as in Caucasians [15], [25], 
while the association between HLA-B*15:02 and 
carbamazepine has been only observed in Asian 
ancestries [14], [15], [18], [23], [26]. We found 15% of 
SJS/TEN patients (nine patients) having HLA-B*46:01 
allele, which is similar to the findings from the previous 
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studies among Vietnamese [20], Korean [23], and 
Thai [24]. A study in Vietnam shows that the prevalence 
of HLA-B*46:01 in the carbamazepine-induced 
SCARs group was significantly lower than that in the 
carbamazepine-tolerant epilepsy patient group [18]. 
This allele may be considered as a protective factor 
against the development of carbamazepine-induced 
SCARs in Vietnamese [18]. However, in our study, 
HLA-B*46:01 allele did not reveal the association with 
carbamazepine-induced SJS/TEN. Therefore, the role 
of HLA-B*46:01 in SCARs needs to be investigated 
further.
We also observed an allopurinol-induced SJS 
patient possessing HLA-B*15:02. In fact, this patient’s 
HLA-B genotype was 15:02 and 58:01. He was at 
high risk of being allergic to both carbamazepine and 
allopurinol. In addition, there were two traditional-
induced SJS/TEN patients and seven unknown drug-
induced SJS/TEN patients all carrying HLA-B*15:02; 
two patients with unknown causative drugs carrying 
HLA-B*58:01. Typing of HLA-B alleles in these patients 
could be significant to avoid the high risk of drug-induced 
SCARs.
In our study, traditional medicine was the 
third most common culprit drug of SJS/TEN (13.3%), 
which is similar to the finding from a previous study in 
Hanoi [27]. Interestingly, among these patients, there 
were six patients with HLA-B*51:02 allele (75%). 
HLA-B*51:02 allele belongs to B5101 serotype. There 
has been no study indicating its role in SJS/TEN so far.
In Vietnam, the use of medications without 
prescriptions is rather common, even mixing of 
western medicines in some traditional medicines 
intentionally done by traditional healers, is not rare. 
Consequently, it is more difficult to identify the offending 
drugs. Therefore, the possible association between 
HLA-B*51:02 allele and traditional medicine-induced 
SJS/TEN needs to be investigated further, and, studies 
about HLA-B genotypes in SCARS are crucial and may 
provide evidences for advising certain patients to avoid 
using certain medications.
We found a significant association between 
carbamazepine-induced SJS/TEN and HLA-B*15:02 
allele. This is consistent with those of other studies 
in Asia [14], [18]. Hence, screening this allele is 
very essential before indicating carbamazepine 
as well as other aromatic anticonvulsant agents 
because among these drugs, cross-reactivity exists 
frequently [28], [29], [30], [31]. In our study, there 
was one patient with lamotrigine-induced TEN who 
took lamotrigine to treat her depressed condition. 
This patient possessed HLA-B*15:21 and HLA-
B*46:01 genotype. In a study among Thai population, 
the prevalence of HLA-B*15:02 and HLA-A*02:07 
alleles has been shown higher in the lamotrigine-
induced SCARs than in the lamotrigine-tolerant control 
group [32]. HLA-B*15:21 allele is an HLA-B75 serotype 
marker similar to HLA-B*15:02, -B*15:11, and -B*15:08, 
they have the same carbamazepine binding sites in 
silico analysis [11]. There was a case report of a Filipino 
carbamazepine-induced SJS/TEN overlap patient 
without HLA-B*15:02 allele but with positive HLA-B75 
serotype [33]. A study in Korean population reveals that 
three out of five lamotrigine-induced SJS/TEN patients 
carry HLA-B*44:03 allele [23]. Out of 60 patients, we 
observed one patient with carbamazepine-induced 
TEN caring this allele. This may be due to the fact that 
there is a difference in HLA-B*44:03 allele frequencies 
between Korean [23] and Vietnamese population [20].
There were some limitations in our study. First, 
the sample size was of 60 SJS/TEN patients but the 
causative drugs varied. Accordingly, we could not focus 
on analyzing a big sample of SJS/TEN patients due to 
a special drug. Second, using the control group of the 
previous study 18 might not be ideal for comparison. 
Third, we typed only HLA-B alleles, but not other HLA 
genes associated with SJS/TEN and SCARs, such as 
HLA-A, HLA-C, or some metabolic genes beyond HLA 
genes.
Conclusion
HLA-B*15:02 was the most common 
HLA-B allele in Vietnamese patients with SJS/TEN. 
HLA-B*51:02 allele may play an important role in the 
pathogenesis of the traditional medicine-induced 
SJS/TEN. There may be a link between HLA-B alleles 
and causative drugs of SJS/TEN. The HLA-B genotypes 
may be useful for suggesting the causative drugs in 
some cases and preventing SCARs.
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